Hunter Associates Investment Management’s AYTU BioPharma AYTU Stock Holding History

Hunter Associates Investment Management’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-544	Closed	-$2K	–	259
2022 Q4	$2K	Hold	544	–	–	﹤0.01%	231
2022 Q3	$2K	Hold	544	–	–	﹤0.01%	221
2022 Q2	$8K	Hold	544	–	–	﹤0.01%	226
2022 Q1	$12K	Hold	544	–	–	﹤0.01%	145
2021 Q4	$15K	Hold	544	–	–	﹤0.01%	155
2021 Q3	$31K	Hold	544	–	–	0.01%	148
2021 Q2	$55K	Hold	544	–	–	0.02%	138
2021 Q1	$83K	Buy	+544	New	+$86.4K	0.02%	202

Other funds holding AYTU

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Hunter Associates Investment Management's AYTU Position: Q1 2023 in Review

Hunter Associates Investment Management sold out of AYTU BioPharma (AYTU) in Q1 2023, closing a stake of 544 shares — an estimated $2K sold.

Hunter Associates Investment Management first reported a position in AYTU in Q1 2021 and held it in 8 quarters. The position peaked at $83K in Q1 2021. 21 funds tracked by Wall St. Rank hold AYTU as of Q1 2023.

Hunter Associates Investment Management reported no remaining AYTU BioPharma position as of Q1 2023 after selling out during the quarter.
Hunter Associates Investment Management sold 544 AYTU BioPharma shares in Q1 2023, an estimated $2K.
Hunter Associates Investment Management first reported a position in AYTU BioPharma in Q1 2021 and held it in 8 quarters.
Hunter Associates Investment Management's AYTU BioPharma position peaked at $83K in Q1 2021.
21 funds tracked by Wall St. Rank held AYTU BioPharma as of Q1 2023.

Based on Hunter Associates Investment Management's 13F filing for Q1 2023, filed 2 May 2023.